Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. (NYSE: CAH) is a global leader in integrated healthcare services and products. With nearly 100 years of experience, the company stands as a pillar in the healthcare industry, ranking among the top 25 on the Fortune 500 list. Cardinal Health offers a comprehensive suite of services that cater to hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices worldwide.
Operating through two main segments—Pharmaceuticals and Medical—Cardinal Health provides clinically-proven medical products and pharmaceuticals, alongside cost-effective solutions that enhance supply chain efficiency. The company is a major distributor of branded, generic, and specialty pharmaceutical products to a wide array of clients, including retail chains, independent pharmacies, hospital networks, and healthcare providers.
Recently, Cardinal Health reported strong financial results for Q2 FY2024, with a 12% increase in revenue to $57.4 billion. The company also saw significant growth in both its Pharmaceutical and Medical segments, driven by robust sales of brand and specialty pharmaceuticals, as well as improvements in at-Home Solutions and Global Medical Products and Distribution. CEO Jason Hollar highlighted the company's operational execution and strategic priorities, which include tech-enabled specialty acquisitions and a focus on supply chain resiliency.
Cardinal Health is also committed to sustainability and corporate responsibility. The company recently released its Fiscal 2023 Environmental, Social and Governance (ESG) Report, emphasizing long-term value creation through sustainable practices. The company has received approval from the Science Based Targets initiative (SBTi) for its ambitious greenhouse gas (GHG) emissions reduction targets. By FY2023, Cardinal Health had already reduced its Scope 1 and 2 emissions by 13% from a FY2019 base year.
In terms of infrastructure, Cardinal Health is expanding its logistics capabilities. The company has commenced construction on a new 350,000 square-foot Consumer Health Logistics Center in Columbus, Ohio, designed to support the distribution of over-the-counter consumer health products. This facility, expected to be operational by Summer 2025, will create approximately 100 new jobs and enhance Cardinal Health's supply chain agility.
Despite challenges such as the non-renewal of its pharmaceutical distribution contracts with OptumRx, Cardinal Health remains resilient. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance and is confident in its long-term growth targets.
For more information, visit cardinalhealth.com and follow @cardinalhealth on Twitter.
Cardinal Health (NYSE: CAH) has announced a quarterly dividend of $0.4908 per share, set to be paid on January 15, 2022. Shareholders must be on record by the close of business on January 3, 2022 to receive this payment. This decision reflects the company’s commitment to returning value to its shareholders.
Cardinal Health emphasizes the significance of biosimilars in enhancing healthcare access during the second annual Global Biosimilars Week. Biosimilars, which are FDA-approved treatments that mirror biologics, play a vital role in reducing U.S. drug costs, projected to save $133 billion by 2025. Currently, there are 31 FDA-approved biosimilars in the U.S., with 20 available in the market, primarily targeting cancer and autoimmune diseases. Their anticipated entry into diabetes and ophthalmology markets promises lower treatment costs for millions of patients. Cardinal Health's leadership in the biosimilars sector aims to foster competition and innovation.
Suzanne Foster, president of
Cardinal Health (NYSE: CAH) has secured a $750,000 contract from the FDA for an 18-month study examining real-world evidence (RWE) in lymphoma treatment. The study, titled 'Assessment of a Novel Methodology for Endpoints Assessing Response to Lymphoma Treatment in Real-World Studies,' aims to compare real-world data (RWD) with central review standards in clinical trials. This initiative supports the FDA's increasing focus on RWE following the 21st Century Cures Act and seeks to improve patient outcomes through enhanced regulatory decision-making.
Cardinal Health (NYSE: CAH) announced a new range of cancer screening options in collaboration with FUJIFILM Healthcare and Polymedco. These options aim to address the significant decline in cancer screenings caused by the pandemic, which saw nearly 10 million screenings missed in the U.S. alone. The company now offers at-home testing for colon cancer, reducing barriers to early detection. Additionally, it provides solutions for liver cancer surveillance, critical for at-risk patients. Cardinal Health emphasizes the importance of accessible diagnostics to improve healthcare outcomes.
Journey Biosciences announced a collaboration with Cardinal Health's OptiFreight® Logistics to enhance kidney disease diagnostics for diabetes patients. This partnership aims to deliver the innovative NaviDKD diagnostic screening technology to healthcare providers, facilitating proactive management of Diabetic Kidney Disease (DKD). The deal focuses on improving logistics management, which is critical for timely diagnostics. Journey Biosciences seeks to transform diabetes care from reactive to proactive, emphasizing early detection and risk reduction.
Cardinal Health (NYSE: CAH) has expanded its Strategic Stock Solution, now serving nearly 40 hospitals and health systems nationwide, just a year after launch. This solution addresses challenges in pandemic preparedness by allowing health systems to order and store critical supplies, ensuring deliveries within 72 hours. Key features include inventory management using real-time analytics and significant logistical support. With a focus on enhancing supply chain resiliency, Cardinal Health aims to prepare medical facilities for future health emergencies, including the upcoming flu and RSV season.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Cherokee Nation for approximately $75 million over 6.5 years. This agreement resolves ongoing litigation and allows the companies to focus on safe medication delivery. The settlement is part of broader negotiations with federally recognized Native American tribes, despite the companies disputing the allegations against them. The firms emphasize their commitment to addressing the opioid epidemic's impact on communities.
Cardinal Health (NYSE: CAH) will release its first-quarter financial results for fiscal year 2022 on November 9, prior to market opening. A webcast discussion will follow at 8:30 a.m. Eastern. Investors can access the webcast and presentation through the Investor Relations page. Replay of the presentation will be available until November 8, 2022. Cardinal Health is a key player in the healthcare sector, distributing pharmaceuticals and manufacturing medical products globally.
FAQ
What is the current stock price of Cardinal Health (CAH)?
What is the market cap of Cardinal Health (CAH)?
What services does Cardinal Health offer?
How did Cardinal Health perform in Q2 FY2024?
What is Cardinal Health's approach to sustainability?
What are Cardinal Health's main business segments?
What recent infrastructure developments has Cardinal Health announced?
How many employees does Cardinal Health have?
What are Cardinal Health's fiscal 2024 guidance and expectations?
How is Cardinal Health addressing supply chain efficiency?
What impact will the non-renewal of OptumRx contracts have on Cardinal Health?
Where can I find more information about Cardinal Health?
